Articles
7,961 Articles
Psilocybin Alpha
/
May 12, 2025
Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic Summit (Part 2)
From 17–19 April, the UK’s seventh biennial psychedelic conference tackled some of the field’s most urgent questions.In this second instalment, we explore: ***Words by Charles Bliss for Psychedelic Alpha. Every year on 19 April, psychonauts and scientists alike mark Bicycle Day—the...
Beckley Foundation
/
May 12, 2025
A message from Amanda
Dear friends, Some of you may know that I was undergoing immunotherapy treatment against liver cancer for the best part of last year, during which time I continued to work on the Beckley Foundation’s exciting collaborative research programmes. Unfortunately, however, the treatment has not...
LSD
Psilocybin Alpha
/
May 09, 2025
Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on Psychedelics Plans
Yesterday, Japanese pharmaceutical giant Otsuka announced a joint research agreement with Keio University aimed at building infrastructure for “the social implementation of psychedelics in Japan.” The non-clinical research agreement will see the pair focus on four key areas: It appears, then,...
Psychedelics
DoubleBlind Mag
/
May 09, 2025
How Psychedelics Affect Time, Grief, and the Earth
How Psychedelics Affect Time, Grief, and the Earth A journey into the void changed how one environmentalist saw time, grief, and life on Earth. Mattha Busby 09 May Deep dives and investigations you won't find anywhere else Can Psychedelics Help Us Cope with Climate Collapse? Climate...
Psychedelics
Microdose
/
May 08, 2025
A Psychedelic Turning Point: How a Landmark Review Re‑frames Psilocybin’s Role in Treating Addiction
Substance‑use disorders (SUDs) now affect nearly 40 million people worldwide and account for millions of deaths each year, yet the standard therapeutic toolbox—counselling, cognitive‑behavioural therapy, and a handful of pharmacotherapies such as methadone, buprenorphine, naltrexone and...
DoubleBlind Mag
/
May 07, 2025
There’s A New Drug Club Kids Are Obsessed With
There's A New Drug Club Kids Are Obsessed With Meet the latest synthetic club drug fueling all-night parties. Michelle Lhooq 07 May Your weekly dose of psychedelic insights and news WTF is 3-MMC, Berlin’s Weird New Club Drug? Introducing the latest trending synthetic blowing up...
LSD
MDMA
Psilocybin Alpha
/
May 06, 2025
EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic Access for Veterans
Following last summer’s FDA rejection of MDMA-assisted therapy for PTSD, veteran-led advocacy groups Healing Breakthrough and Heroic Hearts Project are uniting. In this exclusive interview, Jesse Gould and Juliana Mercer say the fight is far from over—and that healing shouldn’t require a...
Psychedelics Today
/
May 06, 2025
Ibogaine – The Promise, the Protocol, and Protecting the Sacred
Aspen Psychedelic Symposium 2024 – Hosted by Kevin Franciotti This panel explores the healing power of Ibogaine, a powerful plant medicine used for addiction recovery and spiritual growth. Moderator Kevin Franciotti leads a thoughtful conversation with Talia Eisenberg, Tom Feegel, and Dr. Lola...
DoubleBlind Mag
/
May 05, 2025
What Psilocybin Might Offer That SSRIs Don’t
What Psilocybin Might Offer That SSRIs Don’t Here’s how psilocybin-assisted therapy and traditional antidepressants affect our brain’s response to joy, surprise, and emotional nuance, according to science. Mary Carreon // Senior Editor 05 May Good morning! Thanks for reading another...
Psilocybin
LSD
Psychedelics
DoubleBlind Mag
/
May 02, 2025
Can Psychedelics Help Unlock Solutions to Global Crises?
Can Psychedelics Help Unlock Solutions to Global Crises? If psychedelics help us remember what we already know, could that clarity help us tackle the world’s biggest problems? Saga Briggs 02 May Deep dives and investigations you won't find anywhere else Can Psychedelics Help Us Solve...
Psychedelics
Psilocybin Alpha
/
May 02, 2025
Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business of Psychedelics, Bitcoin
On Wednesday, President Trump livestreamed a meeting in which members of his cabinet—seated around a table with various colourways of GULF OF AMERICA caps in front of them—provided updates from their first 100 days in office. When the circle reached VA Secretary Doug Collins, Trump asked: “How...
Psychedelics
Psychedelics Today
/
May 01, 2025
“Neuropharmacology: Psychedelics on the Brain” – Jim Harris, Rachel Zoeller, DPT, David W. Mcmillan, Ph.D., and Manesh Girn, Ph.D.
A panel discussion with Jim Harris, Rachel Zoeller, DPT, David W. McMillan, Ph.D., and Manesh Girn, Ph.D.Recorded live at the Aspen Psychedelic Symposium In this riveting and deeply personal conversation, moderator Jim Harris is joined by three pioneers at the intersection of neuroscience,...
Psychedelics
Psilocybin Alpha
/
May 01, 2025
March & April 2025 Psychedelic Patent Update: Lykos’ Patent Woes Continue; Filings Provide First Look at Seaport’s 2-Bromo-LSD Program; Delix’s Ergoline Analogues; CaaMTech’s Spinout
Written by Psychedelic Alpha’s Noah Smith with support from Editor-at-Large and patent attorney Graham Pechenik of Calyx Law. The Psychedelic Patent Update provides headline figures and data regarding published psychedelic patent applications and grants, as well as a brief summary of a select...
Psychedelic Invest
/
Apr 30, 2025
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated...
Psilocybin
Psychedelic Invest
/
Apr 30, 2025
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26,...
Ketamine
DoubleBlind Mag
/
Apr 30, 2025
Did You Know Women Made Acid with Owsley?
Did You Know Women Made Acid with Owsley? Rhoney Stanley is one of them, and she helped fuel the '60s psychedelic revolution. Madison Margolin 30 Apr SUPPORTING PARTNER Your weekly dose of psychedelic insights and news Meet Rhoney Stanley, Underground LSD Chemist Behind the ‘60s...
LSD
Psychedelic Invest
/
Apr 30, 2025
PharmAla Issues Q2 Financial Statements
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is...
MDMA
Psychedelic Invest
/
Apr 30, 2025
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its...
Psychedelics Today
/
Apr 29, 2025
Understanding Our Roots and Respecting Indigenous Wisdom
In this special panel, Joe Moore from Psychedelics Today is joined by Sandor Iron Rope and Zach Leary. Sandor is a Lakota spiritual leader and peyote practitioner. Meanwhile, Zach is a writer and advocate for psychedelic culture. Together, they explore why it is essential to respect the roots of...
Psychedelics
Microdose
/
Apr 28, 2025
The New Epidemic: How Trauma and Digital Exposure Are Shaping a Teen Mental Health Crisis
At a time when adolescent mental health is reaching a breaking point, it’s more important than ever to understand the forces shaping this growing crisis. I’m honored to introduce an article by Michael Villarreal, CADC, CEO of Tres Vistas Recovery, who brings both professional expertise and a...
DoubleBlind Mag
/
Apr 28, 2025
Is Coca the Secret to Unlocking the Plant Codex?
Is Coca the Secret to Unlocking the Plant Codex? PLUS, psychedelics and chronic health, synthetic vs. natural, and working with Morning Glory. Mary Carreon // Senior Editor 28 Apr Babe, wake up! A new edition of The Drop In by DoubleBlind Mag is here, and it’s loaded with independent...
Psilocybin
LSD
Psychedelics
Lucid News
/
Apr 27, 2025
Disconnection Meets Dialogue at Breaking Convention 2025
Stepping onto the sun-warmed lawns of the University of Exeter’s Streatham Campus, I felt the conference’s promise before the blotter-paper badge swung around my neck: a riot of color, a buzz of anticipation, and, beneath it all, a palpable yearning for reconnection. In an era when...
LSD
Psilocybin Alpha
/
Apr 25, 2025
Pα+ Psychedelic Bulletin #194: Make-or-Break Moment Looms for Compass; RFK Jr. Discusses LSD Use; Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona
A few weeks ago I (Josh Hardman) had the privilege of attending a Design Thinking Workshop at IESE Business School in Barcelona as part of PsyPal, an EU-funded project that revolves around a study of psilocybin therapy for psychological distress in palliative care patients. (For a refresher on the...
Psilocybin
LSD
DoubleBlind Mag
/
Apr 25, 2025
Are Patients Accidentally Tripping on Ketamine in the ER?
Are Patients Accidentally Tripping on Ketamine in the ER? Reports of patients tripping on ketamine during emergency care are raising new questions about the medical field’s readiness for psychedelic experiences. Reilly Capps 25 Apr Deep dives and investigations you won't find anywhere...
Ketamine
Psychedelics Today
/
Apr 24, 2025
Diane Goldstein, Sarko Gergerian and Rick Doblin
This podcast comes from the Aspen Psychedelic Symposium from last summer. It features Diane Goldstein who is the executive director of Law Enforcement Action Partnership, Sarko Gergerian a police officer from Winthrop, Mass and Rick Doblin from MAPS. This panel was introduced by Zach Leary and was a...
Psychedelics Today
/
Apr 24, 2025
Psychedelic Science 2025: A Convergence of Data, Discovery, and Integration
On June 16, 2025, thousands of researchers, clinicians, therapists, policymakers, and advocates will converge in Denver, Colorado, for Psychedelic Science 2025: The Integration, the world’s most important gathering focused on psychedelic medicine and research. Hosted by the Multidisciplinary...
Psychedelic Invest
/
Apr 23, 2025
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
Psychedelic Invest
/
Apr 23, 2025
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a...
Psychedelic Invest
/
Apr 23, 2025
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical...
Psychedelic Invest
/
Apr 23, 2025
Revive Therapeutics Announces Proposed Shares for Debt Transaction
TORONTO, April 21, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical...
Psilocybin
Psychedelic Invest
/
Apr 23, 2025
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
Vancouver, Canada, April 23, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
DoubleBlind Mag
/
Apr 23, 2025
What to Know About Changa, the Smokable “Ayahuasca”
What to Know About Changa, the Smokable "Ayahuasca" Changa blends DMT with smokable herbs, but its origins, risks, and connection to traditional ayahuasca are more complicated than they seem. Anna Wilcox 23 Apr Your weekly dose of psychedelic insights and news Everything You Need to Know...
DMT
Ayahuasca
Psychedelic Invest
/
Apr 23, 2025
Tryptamine Therapeutics to Launch Groundbreaking Trial for Binge Eating Disorder Treatment
Tryptamine Therapeutics has signed an agreement with Swinburne University to conduct a world-first clinical trial assessing the safety and efficacy of TRP-8803, an IV-infused psilocin formulation, for treating Binge Eating Disorder (BED). This trial, which follows promising results from a previous...
Tryptamine
Psychedelic Invest
/
Apr 23, 2025
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today...
Psychedelic Invest
/
Apr 23, 2025
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Toronto, Ontario–(Newsfile Corp. – January 27, 2025) – Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, is pleased to...
Psychedelic Invest
/
Apr 23, 2025
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
Vancouver, Canada, April 21, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased...
Psychedelics
